Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...

The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Remibrutinib results in significant improvement in composite measure of itching and hives after second-generation H1-antihistamine treatment.

Duke University blood cancer specialist Lindsay Rein, MD, has developed a rare expertise in myeloproliferative neoplasms ...

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

Harrington Prize for Innovation in Medicine has been awarded to Owen N. Witte, MD, Distinguished University Professor and President's Chair in Developmental Immunology, David Geffen School of Medicine ...

Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

Case Bruton of Netflix’s ‘Temptation Island‘ was one of the tempters who was present in the women’s villa to try and sway them. From the very start, he made a lasting impression with his calm ...